NCT04983368 - A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

February 11, 2022

Study Completion Date

February 11, 2022

Conditions

Mild Cognitive ImpairmentAlzheimer's Disease

Interventions

DRUG

Xanamem® 5 mg

"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."

DRUG

Placebo

Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.

DRUG

Xanamem® 10 mg

"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."

Trial Locations (5)

Paratus Clinical Research Western Sydney, Blacktown

Paratus Clinical Research Central Coast, Kanwal

Paratus Clinical Research Canberra, Bruce

Paratus Clinical Research Brisbane, Albion

USC Clinical Trials, Sippy Downs